|
|
市场分析报告
|
2020 Friedreich Ataxia Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs ... (Sodium phenylbutyrate and tauroursodeoxycholic acid ), vatiquinone (EPI-743), BMN290, BVA202, BVA203 ...
2020 Rett Syndrome Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs ... ), Rett fusion protein, AVXS-201, vatiquinone (EPI-743), BHV-5000, BXCL902 ...
Leigh disease - Pipeline Insight, 2021 ... releases. Leigh disease Emerging Drugs Vatiquinone (EPI-743): PTC Therapeutics EPI ... Taysha Gene Therapies Key Products Vatiquinone (EPI-743) ABI-009 Sonlicromanol ...
Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024 May 2024
Friedreich's Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 ... antioxidant responses, and reduce inflammation. Vatiquinone is a small molecule, first-in-class selective ...
Global Friedreich's Ataxia (FA) Market - 2025 -2033 ... study. PTC Therapeutics’ oral agent vatiquinone (PTC 743) also pushed forward ... New Drug Application (NDA) for vatiquinone to the U.S. Food and Drug Administration ...
Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major ataxia markets reached a value of US$ 23.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 43.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.49% during 2024-2034. The ataxia market has been comprehensively ...
Leigh Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major leigh syndrome markets reached a value of US$ 105.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 175.1 Million by 2034, exhibiting a growth rate (CAGR) of 4.76% during 2024-2034. The Leigh syndrome market has been ...
MELAS Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 ... the United States and Europe. Vatiquinone, under development for the treatment ...
PTC Therapeutics Inc (PTCT) - Financial and Strategic SWOT Analysis Review ... of huntington’s disease; PTC857 for treatment of vatiquinone in children with mitochondrial disease; PTC596 ...
|
|
|
|